Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to HK Equities

HK Equities · Finance research note

HKEX 8603 - Fameglow Holdings Ltd.

Research and analysis only
View analysis Browse HK Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) 527.55%
Risk / Std Dev (Ann.) 78.42%

Price Snapshot:

Metric Value
Last Price 6.570 HKD
Day Change -0.010 (-0.15%)

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2026 FY2025
Revenue Reported revenue HK$589.79M HK$435.27M
Net income Reported net income HK$54.64M HK$45.73M
Total assets Year-end reported balance HK$456.90M HK$329.81M
Shareholders’ equity Year-end reported balance HK$207.06M HK$106.09M
Net margin Net income ÷ revenue 9.26% 10.51%
Asset turnover Revenue ÷ total assets 1.2908x 1.3198x
Equity multiplier Total assets ÷ shareholders’ equity 2.2066x 3.1088x
ROE Net margin × asset turnover × equity multiplier 26.39% 43.10%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue HK$589.79M
Prior annual revenue HK$435.27M
EBIT HK$66.58M
Tax rate 11.88%
NOPAT = EBIT × (1 − tax rate) HK$58.67M
Forecast start-growth basis 15.00%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT HK$58.67M
Add: depreciation & amortisation HK$80.46M
Less: capital expenditure -HK$68.07M
Less/(add): working-capital cash-flow movement -HK$20.88M
Current unlevered FCFF HK$50.18M

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 15.00% HK$67.47M HK$92.53M -HK$78.28M -HK$24.02M HK$57.70M HK$55.85M
2 11.88% HK$75.48M HK$103.52M -HK$91.56M -HK$26.87M HK$60.57M HK$54.91M
3 8.75% HK$82.09M HK$112.58M -HK$103.91M -HK$29.22M HK$61.54M HK$52.25M
4 5.62% HK$86.70M HK$118.91M -HK$114.33M -HK$30.86M HK$60.42M HK$48.05M
5 2.50% HK$88.87M HK$121.88M -HK$121.88M -HK$31.63M HK$57.24M HK$42.64M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.38
Cost of equity 6.79%
Pre-tax cost of debt 4.32%
WACC 6.76%
WACC validation requires assumption review

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value HK$1.38B
Implied terminal EV / EBITDA 6.18x
Terminal value as % of enterprise value 79.64%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF HK$253.69M
Present value of terminal value HK$992.17M
Indicated enterprise value HK$1.25B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value HK$1.25B
Less: gross interest-bearing debt HK$119.18M
Add: cash and equivalents HK$110.69M
Add: affiliate investments HK$0.00
Less: minority interests HK$0.00
Indicated common equity value HK$1.24B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 818,920,000.00
Share-count basis reported shares outstanding; option/RSU dilution data not separately available
Current market price HK$14.30
DCF indicative value per share HK$1.51
Indicative value vs. market price -89.43%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range review required
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:17:36.597943 UTC; latest reported fiscal period: 2026-03-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Factor-model exception: No sufficiently aligned issuer-return and regional factor-return sample is available. No Fama–French loading or alpha estimate is published on an incomplete basis.

Factor models are descriptive in-sample exposure diagnostics, not forecasts, investment recommendations, or estimates of future returns. This is research and analysis only, not personalized financial advice.

hkexstockequity8603